- Email: [email protected]
ROLE OF ASCORBIC ACID ON HYPERCHOLESTEROLEMIA INDUCED ATHEROSCLEROSIS
Poster Sessions PO39 Novel therapies for CVD prevention tests of platelets aggregation with ADP diluted down to 2,5µM, 1,25µM and 0,625µM, the total number of samples amounted to 88. Results: In PFA-100 analysis closure time (CT) values were prolonged after separation in all cases but it was not statistically significant. Modified platelets aggregation outcome was significantly improved. Conclusion: Investigation of primary haemostasis using PFA-100 analyzer seems to be not significant in our study (p<0,14). Modified platelets aggregation seems to be more suitable marker to determine the optimal intensity of individual LDL-apheresis with statistically significantly improved results (p<0.05). Supported by: MZO 00179906 and 0021620820, IGAMHCZZCR NR/8062-3, NR/8505-3, NR/9103-4. PO39-617
ROLE OF ASCORBIC ACID ON HYPERCHOLESTEROLEMIA INDUCED ATHEROSCLEROSIS
A. Manocha, S. Das, S. Bhargava, M. Kankra, L.M. Srivastava. Biochemistry Department, Sir Ganga Ram Hospital, Rajender Nagar, New Delhi, India
PO39-618
THE EFFECT OF ETHANOL EXTRACT OF GLYCYRRHIZA GLABRA ON LIPID PROFILE AND CARDIOVASCULAR FATTY STREAK FORMATION IN YPERCHOLESTEROLEMIC RABBITS
N. Jafari Dinani 1 , S. Asgary 1 , H. Madani 2 . 1 Basic Science Dept., Isfahan Cardiovascular Research Center, Sedigheh Tahere Hospital, Isfahan, Iran; 2 Biology Dept., The University of Isfahan, Isfahan, Iran Background and aims: Atherosclerosis which results from gradual deposition of lipids in medium and large arteries is a leading cause of mortality worldwide. Glycyrrhiza glabra is an herb of Fabacea family which contain hypolipidemic compounds and flavonoids with high antioxidative properties. This study was conducted to determine the effect of Glycyrrhiza glabra extract on blood lipids and atherosclerosis in rabbits fed with high cholesterol diet. Methods: Fifteen male rabbits were randomly divided into three groups (normal diet group, highcholesterol diet (1% cholesterol) and a group which received high-cholesterol diet supplemented with Glycyrrhiza glabra extract (50 mg/kg body weight). The concentration of Total cholesterol (TC), LDL cholesterol, triglycerides (TG) and HDL cholesterol was determined in rabbits at the start of the experiment, and at the end of the first and second month of the study. At the end of the experimental period the aorta was removed for assessment of atherosclerotic plaques. Results: Glycyrrhiza glabra significantly decreases TC, LDL and TG levels and increase HDL and lessens atherosclerotic lesion in aorta. Hence Glycyrrhiza glabra extract can effectively prevent the progress of atherosclerosis.
Coclusions: This is likely due to the effect of Glycyrrhiza glabra on plasma lipoproteins and its antioxidant and anti-inflammatory properties. PO39-619
LONG-TERM LIPIDAPHERESIS IN PATIENTS WITH CVD AND ELEVATED LIPOPROTEIN(A)
A. Vogt, F. Barz, E. Steinhagen-Thiessen, U. Kassner. Lipiddepartment, Charite, Berlin, Germany Background: Elevated levels of lipoprotein(a) (Lp(a)) are associated with premature cardiovascular disease (CVD). Therapeutic options are still limited. Significant reductions can be achieved via lipidapheresis (LA). Indication of LA: Clinical and short term findings show, that patients with elevated Lp(a) and CVD benefit from LA. Due to lacking randomized trials the indication for LA in these patients is not established. Method: 15 CVD-patients of our lipid-department, whose indication for weekly LA is an elevated level of Lp(a) (> 60 mg/dl) with LDL < 100 mg/dl and TG < 250 mg (with medication), were evaluated retrospectively. Baseline characteristics: age: 52,67 yr (mean, 37 - 68 yr); first CVD event: 41,8 years (mean, 31 – 60 yr); CVD events: 1,93 (mean, 0 - 7, sum: 29); interventions before LA: 5,8 (mean, 2 - 19, sum: 87); Lipids: LDL-Cholesterol 70,87 mg/dl, Lp(a) 126,1 (mean each); duration of LA: 3,74 yr (mean, 1 - 12,8 yr). Results: LDL-Cholesterol and Lp(a) are reduced safely and markedly by LA (LDL - 43,16%, Lp(a) - 44,73%; mean). Mean pre-LA Lp(a)-levels are reduced by 22,4% (n=15) and 13,36% (n=6) after one and three years of LA, respectively. After initiation of LA interventions were reduced by 88,45% to 0,67 (mean, 0 - 4, sum: 10), no acute event occurred. Conclusions: These results show convincingly that weekly LA is safe and beneficial in highrisk patients with CVD, elevated Lp(a), and LDL at targetlevel. Cardiovasvular events and interventions are reduced markedly. To establish LA-therapy in these patients further studies are needed. PO39-620
ALPHA-LIPOIC ACID AND NICOTINAMIDE IN THE TREATMENT OF CARDIOVASCULAR AUTONOMIC NEUROPATHY IN TYPE 2 DIABETIC PATIENTS
A. Serhiyenko, V. Serhiyenko, L. Serhiyenko. Department of Endocrinology State Medical University, Lviv, Ukraine Background and Aims: The present study has examined the effect of α-lipoic acid (ALA) and nicotinamide (NA) on the heart rate variability (HRV), superoxide dismutase (SOD), gluthation peroxidase (GPO), catalase activities, reduced gluthatione (GSH), malondialdegide (MDA) contents in the RBCs’ in Type 2 diabetic patients (T2DM) with cardiovascular autonomic neuropathy (CAN). Materials and methods: 59 patients with T2DM and CAN (59,3±7,9 years) were allocated to three treatment group: (1) daily per os dose of ALA 600 mg (n=29); (2) NA 700 mg (n=18); (3) ALA 600 mg and NA 700 mg (n=12) during 2 months. Statistics: ANOVA. Results: The progress of CAN is accompanied by decrease of the activities of SOD (7,38±0,29, p<0,001), GPO and catalase (p<0,001), the content of GSH and increase of the MDA (p<0, 001) in RBC’s. After 2 months of a treatment course with ALA it the increasing spectral power in the low- and high frequency (p<0,01), coefficient of variation (p<0,05). Simultaneously, activity of SOD, GPO (p<0,001) and GSH concentration were authentically augmented, and the contents of MDA, QTc interval parameters (0,52±0,057, p<0,05) was reduced (p<0,01). Simultaneously introduction of NA and ALA is conducted with more significant increasing SOD: 9,14±1,25 IU/ml Rbc’s, p<0, 001; GPO - 298,14±19,45 mcmol GSH/min Hb, p<0,001) and GSH concentration (1,97±0,04 mcM/g Hb, p<0,001), TRAC (p<0,001), HRV, decreasing of MDA concentration (p<0,001) and QTc interval parameters. Conclusion: Usage of ALA and NA is accompanied by improvement of HRV, QTc interval, antioxidant defence parameters and may be used for the treatment of CAN.
77th Congress of the European Atherosclerosis Society, April 26–29, 2008, Istanbul, Turkey
POSTER SESSIONS
Background and Aims: The notion that oxidation of lipids and propagation of free radicals may contribute to the pathogenesis of atherosclerosis is supported by a large body of evidence. To circumvent the damage caused by oxygen free radicals, antioxidants are needed which provide the much needed neutralization of free radicals. In this study we have investigated the effect of ascorbic acid on the development of hypercholesterolemia induced atherosclerosis in rabbits and also have studied the role of ascorbic acid on in vitro oxidation of low density lipoprotein (LDL) isolated from normal and hypercholesterolemic subjects. Methods: Rabbits were made hypercholesterolemic by feeding 100 mg cholesterol/day. Different doses of ascorbic acid (0.5 mg and 15 ascorbic acid/100g body weight/day) were administered to these animals for varying time periods. LDL isolated from normal and hypercholesterolemic individuals were oxidized with copper sulphate in absence and presence of different doses of ascorbic acid. Results: Low dose of ascorbic acid (0.5 mg) in rabbits did not have any significant effect on the percentage area covered by atherosclerotic plaque. However ascorbic acid when fed at a higher dose (15 mg) was highly effective. The LDL isolated from hypercholesterolemic patients had a higher propensity towards in vitro oxidation. Conclusions: The present study suggests that use of ascorbic acid may have great promise in the prevention of hypercholesterolemia induced atherosclerosis. The observations may be of importance in designing future studies of ascorbic acid supplementation in patients with hypercholesterolemia, which is one of the major risk factors for atherosclerosis.
169
ROLE OF ASCORBIC ACID ON HYPERCHOLESTEROLEMIA INDUCED ATHEROSCLEROSIS
A. Manocha, S. Das, S. Bhargava, M. Kankra, L.M. Srivastava. Biochemistry Department, Sir Ganga Ram Hospital, Rajender Nagar, New Delhi, India
PO39-618
THE EFFECT OF ETHANOL EXTRACT OF GLYCYRRHIZA GLABRA ON LIPID PROFILE AND CARDIOVASCULAR FATTY STREAK FORMATION IN YPERCHOLESTEROLEMIC RABBITS
N. Jafari Dinani 1 , S. Asgary 1 , H. Madani 2 . 1 Basic Science Dept., Isfahan Cardiovascular Research Center, Sedigheh Tahere Hospital, Isfahan, Iran; 2 Biology Dept., The University of Isfahan, Isfahan, Iran Background and aims: Atherosclerosis which results from gradual deposition of lipids in medium and large arteries is a leading cause of mortality worldwide. Glycyrrhiza glabra is an herb of Fabacea family which contain hypolipidemic compounds and flavonoids with high antioxidative properties. This study was conducted to determine the effect of Glycyrrhiza glabra extract on blood lipids and atherosclerosis in rabbits fed with high cholesterol diet. Methods: Fifteen male rabbits were randomly divided into three groups (normal diet group, highcholesterol diet (1% cholesterol) and a group which received high-cholesterol diet supplemented with Glycyrrhiza glabra extract (50 mg/kg body weight). The concentration of Total cholesterol (TC), LDL cholesterol, triglycerides (TG) and HDL cholesterol was determined in rabbits at the start of the experiment, and at the end of the first and second month of the study. At the end of the experimental period the aorta was removed for assessment of atherosclerotic plaques. Results: Glycyrrhiza glabra significantly decreases TC, LDL and TG levels and increase HDL and lessens atherosclerotic lesion in aorta. Hence Glycyrrhiza glabra extract can effectively prevent the progress of atherosclerosis.
Coclusions: This is likely due to the effect of Glycyrrhiza glabra on plasma lipoproteins and its antioxidant and anti-inflammatory properties. PO39-619
LONG-TERM LIPIDAPHERESIS IN PATIENTS WITH CVD AND ELEVATED LIPOPROTEIN(A)
A. Vogt, F. Barz, E. Steinhagen-Thiessen, U. Kassner. Lipiddepartment, Charite, Berlin, Germany Background: Elevated levels of lipoprotein(a) (Lp(a)) are associated with premature cardiovascular disease (CVD). Therapeutic options are still limited. Significant reductions can be achieved via lipidapheresis (LA). Indication of LA: Clinical and short term findings show, that patients with elevated Lp(a) and CVD benefit from LA. Due to lacking randomized trials the indication for LA in these patients is not established. Method: 15 CVD-patients of our lipid-department, whose indication for weekly LA is an elevated level of Lp(a) (> 60 mg/dl) with LDL < 100 mg/dl and TG < 250 mg (with medication), were evaluated retrospectively. Baseline characteristics: age: 52,67 yr (mean, 37 - 68 yr); first CVD event: 41,8 years (mean, 31 – 60 yr); CVD events: 1,93 (mean, 0 - 7, sum: 29); interventions before LA: 5,8 (mean, 2 - 19, sum: 87); Lipids: LDL-Cholesterol 70,87 mg/dl, Lp(a) 126,1 (mean each); duration of LA: 3,74 yr (mean, 1 - 12,8 yr). Results: LDL-Cholesterol and Lp(a) are reduced safely and markedly by LA (LDL - 43,16%, Lp(a) - 44,73%; mean). Mean pre-LA Lp(a)-levels are reduced by 22,4% (n=15) and 13,36% (n=6) after one and three years of LA, respectively. After initiation of LA interventions were reduced by 88,45% to 0,67 (mean, 0 - 4, sum: 10), no acute event occurred. Conclusions: These results show convincingly that weekly LA is safe and beneficial in highrisk patients with CVD, elevated Lp(a), and LDL at targetlevel. Cardiovasvular events and interventions are reduced markedly. To establish LA-therapy in these patients further studies are needed. PO39-620
ALPHA-LIPOIC ACID AND NICOTINAMIDE IN THE TREATMENT OF CARDIOVASCULAR AUTONOMIC NEUROPATHY IN TYPE 2 DIABETIC PATIENTS
A. Serhiyenko, V. Serhiyenko, L. Serhiyenko. Department of Endocrinology State Medical University, Lviv, Ukraine Background and Aims: The present study has examined the effect of α-lipoic acid (ALA) and nicotinamide (NA) on the heart rate variability (HRV), superoxide dismutase (SOD), gluthation peroxidase (GPO), catalase activities, reduced gluthatione (GSH), malondialdegide (MDA) contents in the RBCs’ in Type 2 diabetic patients (T2DM) with cardiovascular autonomic neuropathy (CAN). Materials and methods: 59 patients with T2DM and CAN (59,3±7,9 years) were allocated to three treatment group: (1) daily per os dose of ALA 600 mg (n=29); (2) NA 700 mg (n=18); (3) ALA 600 mg and NA 700 mg (n=12) during 2 months. Statistics: ANOVA. Results: The progress of CAN is accompanied by decrease of the activities of SOD (7,38±0,29, p<0,001), GPO and catalase (p<0,001), the content of GSH and increase of the MDA (p<0, 001) in RBC’s. After 2 months of a treatment course with ALA it the increasing spectral power in the low- and high frequency (p<0,01), coefficient of variation (p<0,05). Simultaneously, activity of SOD, GPO (p<0,001) and GSH concentration were authentically augmented, and the contents of MDA, QTc interval parameters (0,52±0,057, p<0,05) was reduced (p<0,01). Simultaneously introduction of NA and ALA is conducted with more significant increasing SOD: 9,14±1,25 IU/ml Rbc’s, p<0, 001; GPO - 298,14±19,45 mcmol GSH/min Hb, p<0,001) and GSH concentration (1,97±0,04 mcM/g Hb, p<0,001), TRAC (p<0,001), HRV, decreasing of MDA concentration (p<0,001) and QTc interval parameters. Conclusion: Usage of ALA and NA is accompanied by improvement of HRV, QTc interval, antioxidant defence parameters and may be used for the treatment of CAN.
77th Congress of the European Atherosclerosis Society, April 26–29, 2008, Istanbul, Turkey
POSTER SESSIONS
Background and Aims: The notion that oxidation of lipids and propagation of free radicals may contribute to the pathogenesis of atherosclerosis is supported by a large body of evidence. To circumvent the damage caused by oxygen free radicals, antioxidants are needed which provide the much needed neutralization of free radicals. In this study we have investigated the effect of ascorbic acid on the development of hypercholesterolemia induced atherosclerosis in rabbits and also have studied the role of ascorbic acid on in vitro oxidation of low density lipoprotein (LDL) isolated from normal and hypercholesterolemic subjects. Methods: Rabbits were made hypercholesterolemic by feeding 100 mg cholesterol/day. Different doses of ascorbic acid (0.5 mg and 15 ascorbic acid/100g body weight/day) were administered to these animals for varying time periods. LDL isolated from normal and hypercholesterolemic individuals were oxidized with copper sulphate in absence and presence of different doses of ascorbic acid. Results: Low dose of ascorbic acid (0.5 mg) in rabbits did not have any significant effect on the percentage area covered by atherosclerotic plaque. However ascorbic acid when fed at a higher dose (15 mg) was highly effective. The LDL isolated from hypercholesterolemic patients had a higher propensity towards in vitro oxidation. Conclusions: The present study suggests that use of ascorbic acid may have great promise in the prevention of hypercholesterolemia induced atherosclerosis. The observations may be of importance in designing future studies of ascorbic acid supplementation in patients with hypercholesterolemia, which is one of the major risk factors for atherosclerosis.
169